PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.

Abstract On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01B), was approved by the Food and Drug Administration for the prevention of herpes zoster in adults aged ≥50 years. The vaccine consists of 2 doses (0.5 mL each), administered intramuscularly, 2-6 months apart (1). On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) recommended the recombinant zoster vaccine (RZV) for use in immunocompetent adults aged ≥50 years.
PMID
Related Publications

Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years.

Update on the advisory committee on immunization practices' recommendations for use of herpes zoster vaccine.

Update on recommendations for use of herpes zoster vaccine.

Authors

Mayor MeshTerms

Practice Guidelines as Topic

Keywords
Journal Title mmwr. morbidity and mortality weekly report
Publication Year Start




PMID- 29370152
OWN - NLM
STAT- MEDLINE
DCOM- 20180126
LR  - 20180126
IS  - 1545-861X (Electronic)
IS  - 0149-2195 (Linking)
VI  - 67
IP  - 3
DP  - 2018 Jan 26
TI  - Recommendations of the Advisory Committee on Immunization Practices for Use of
      Herpes Zoster Vaccines.
PG  - 103-108
LID - 10.15585/mmwr.mm6703a5 [doi]
AB  - On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix,
      GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit
      vaccine containing recombinant glycoprotein E in combination with a novel
      adjuvant (AS01B), was approved by the Food and Drug Administration for the
      prevention of herpes zoster in adults aged >/=50 years. The vaccine consists of 2
      doses (0.5 mL each), administered intramuscularly, 2-6 months apart (1). On
      October 25, 2017, the Advisory Committee on Immunization Practices (ACIP)
      recommended the recombinant zoster vaccine (RZV) for use in immunocompetent
      adults aged >/=50 years.
FAU - Dooling, Kathleen L
AU  - Dooling KL
FAU - Guo, Angela
AU  - Guo A
FAU - Patel, Manisha
AU  - Patel M
FAU - Lee, Grace M
AU  - Lee GM
FAU - Moore, Kelly
AU  - Moore K
FAU - Belongia, Edward A
AU  - Belongia EA
FAU - Harpaz, Rafael
AU  - Harpaz R
LA  - eng
PT  - Journal Article
DEP - 20180126
PL  - United States
TA  - MMWR Morb Mortal Wkly Rep
JT  - MMWR. Morbidity and mortality weekly report
JID - 7802429
RN  - 0 (Herpes Zoster Vaccine)
RN  - 0 (Vaccines, Attenuated)
RN  - 0 (Vaccines, Synthetic)
SB  - IM
MH  - Advisory Committees
MH  - Aged
MH  - Herpes Zoster/*prevention & control
MH  - Herpes Zoster Vaccine/*administration & dosage
MH  - Humans
MH  - Immunization Schedule
MH  - Immunocompetence
MH  - Middle Aged
MH  - *Practice Guidelines as Topic
MH  - United States
MH  - United States Food and Drug Administration
MH  - Vaccines, Attenuated/administration & dosage
MH  - Vaccines, Synthetic/administration & dosage
COIS- No conflicts of interest were reported.
EDAT- 2018/01/26 06:00
MHDA- 2018/01/27 06:00
CRDT- 2018/01/26 06:00
PHST- 2018/01/26 06:00 [entrez]
PHST- 2018/01/26 06:00 [pubmed]
PHST- 2018/01/27 06:00 [medline]
AID - 10.15585/mmwr.mm6703a5 [doi]
PST - epublish
SO  - MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108. doi:
      10.15585/mmwr.mm6703a5.